Markets & Investing
BREAKING: Kentucky To Invest in Ibogaine Treatment for Addiction
Earlier today during a press conference, the Opioid Abatement Advisory Commission held a press conference announcing its intended focus on treatments for…
Earlier today during a press conference, the Opioid Abatement Advisory Commission held a press conference announcing its intended focus on treatments for addiction, most specifically ibogaine treatments for opioid addiction.
Approximately $42 million will be allocated over the next seven years to develop safety protocols and to host clinical trials for ibogaine.
“Ibogaine is an alkaloid derived from three plant sources” found in West African countries. “Anecdotal evidence that is a mountain high and decades wide suggests that ibogaine, within 48 to 72 hours of administration in safe, clinically-controlled conditions, resolves opioid withdrawal syndrome,” exclaimed W. Bryan Hubbard, who chairs the Kentucky Commission.
W. Bryan Hubbard, Kentucky’s Opioid Advisory Commission Chair“If this anecdotal evidence can be clinically validated, ibogaine would represent a transformative therapeutic or treatment of opioid use disorder.”
We’ll continue to follow this story, and other similar cases, as it/they develop.
-
Law & Regulation1 week ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics1 week ago
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Psilocybin1 week ago
California advances bill for psychedelics centers
-
Psilocybin4 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
Psychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics1 week ago
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Psychedelics3 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics4 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID